spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  Axona 

 HSMN NewsFeed - 17 Jun 2024
Raya Therapeutic Announces Supportive Clinical Results of Fasudil (RT1968) in ALS Patients
Biopharmaceuticals Neurology
 HSMN NewsFeed - 9 Mar 2023
QurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 15 Oct 2020
Lilly Announces Agreement to Acquire Disarm Therapeutics
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 28 Sep 2020
AbbVie Receives Orphan Drug and Fast Track Designations from the U.S. Food and Drug Administration for Elezanumab, an Investigational Monoclonal Antibody RGMa Inhibitor, for the Treatment of Spinal Cord Injury
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 7 Nov 2019
EIP Pharma Announces Clinical Trial Results of REVERSE-SD, a Phase 2b Study of Neflamapimod in Early-stage Alzheimer's Disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 5 Feb 2019
Kallyope Inc. Appoints Brett Lauring As Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Oct 2018
CavoGene LifeSciences Licenses Novel Gene Therapy for CNS Disorders
Biopharmaceuticals Neurology Licensing
 HSMN NewsFeed - 23 Jan 2018
Disarm Therapeutics Appoints Thomas Engber as Senior Vice President, Head of Neuropharmacology and Translational Sciences
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 19 Dec 2017
Disarm Therapeutics Appoints Peter Keller Chief Business Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 29 Mar 2017
FDA Approves Genentech’s OCREVUS(TM) (Ocrelizumab) for Relapsing and Primary Progressive Forms of Multiple Sclerosis
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 22 Dec 2016
Positive Phase III Results of Genentech’s Investigational Medicine OCREVUS(TM) (Ocrelizumab) Published in New England Journal of Medicine
Biopharmaceuticals Neurology
 HSMN NewsFeed - 28 Jun 2016
FDA Grants Priority Review for Genentech’s OCREVUS(TM) (ocrelizumab) Biologics License Application
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 8 Mar 2016
Accera Appoints Ernest Wong, Ph.D., as Head of Corporate Development
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 17 Feb 2016
FDA Grants Breakthrough Therapy Designation for Genentech’s Investigational Medicine Ocrelizumab in Primary Progressive Multiple Sclerosis
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 30 Jun 2015
Genentech’s ocrelizumab Significantly Reduced Both Relapses and Disability Progression versus interferon beta-1a (Rebif(R)) in Two Phase III Studies in Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 22 May 2012
EnVivo Pharmaceuticals Appoints Alfred Sandrock, M.D., Ph.D., to Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 3 Jan 2012
Accera, Inc. Elects Industry Veteran Holger Kunze as CEO and as a Member of the Company's Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 5 Oct 2010
Accera, Inc. Appoints Dr. Thomas Werner President & CEO and Announces FDA Acceptance of IND Application for AC-1204 for Mild-to-Moderate Alzheimer's Disease
Biopharmaceuticals Neurology Personnel FDA
 HSMN NewsFeed - 28 Apr 2009
Long-Term Study with COPAXONE Indicated Protective Effect on Brain Tissue in Multiple Sclerosis Patients
Biopharmaceuticals Neurology
 HSMN NewsFeed - 15 Apr 2009
Accera, Inc. Launches Neuera Pharmaceuticals, Inc.
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 4 Feb 2009
COPAXONE(R) is Approved for Treatment of Patients with a First Clinical Event Suggestive of Multiple Sclerosis
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 11 Nov 2008
Accera, Inc. Completes $35 Million Series C Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 4 May 2007
Treatment with COPAXONE(R) Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 12 Dec 2006
Serono Announces Initiation of the Reflex Trial to Evaluate New Formulation of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 Oct 2006
COPAXONE(R) Showed Sustained Benefit on Slowing Brain Tissue Damage in Multiple Sclerosis Patients
Biopharmaceuticals Neurology
 HSMN NewsFeed - 29 Sep 2006
AVONEX(R), the #1 Prescribed Multiple Sclerosis (MS) Therapy Worldwide: New MRI Data Presented
Biopharmaceuticals Neurology
 HSMN NewsFeed - 5 Jul 2006
Geron Presents New Data That Document Progress in Development of Therapeutic Products from Human Embryonic Stem Cells
Biopharmaceuticals Regenerative Medicine
 HSMN NewsFeed - 11 May 2006
Boston Life Sciences, Inc. Solidifies Comprehensive Axon Regeneration Position with Children's Hospital Boston
Biopharmaceuticals Neurology Regenerative Medicine
Return to NewsFeed  

 Additional items found! 7

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 7 additional stories matching:
Axona
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!